Precision BioSciences (DTIL) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Precision BioSciences is set to announce its Q2 2025 earnings on Thursday, August 7th, with analysts predicting a loss of ($0.09) per share and revenue of $6.27 million.
• In the last earnings report, the company reported a significant miss with an EPS of ($2.21) and revenue of only $0.03 million compared to expectations of ($0.43) and $5.00 million, respectively.
• CFO John Alexander Kelly recently sold 14,827 shares of his stock, marking a 16.79% decrease in his position, with current insider ownership at 4.5% of the company's stock.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect Precision BioSciences to post earnings of ($0.09) per share and revenue of $6.27 million for the quarter.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($1.78). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $5.00 million. Precision BioSciences had a negative net margin of 42.99% and a negative return on equity of 69.26%. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Stock Down 2.7%

DTIL stock traded down $0.13 during mid-day trading on Friday, reaching $4.62. The company had a trading volume of 61,917 shares, compared to its average volume of 349,790. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.62 and a current ratio of 6.62. The company has a market capitalization of $51.23 million, a price-to-earnings ratio of -2.30 and a beta of 1.43. The firm has a fifty day simple moving average of $4.75 and a 200 day simple moving average of $4.95. Precision BioSciences has a fifty-two week low of $3.61 and a fifty-two week high of $11.09.

Insider Transactions at Precision BioSciences

In other news, CFO John Alexander Kelly sold 14,827 shares of the stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.26, for a total value of $63,163.02. Following the transaction, the chief financial officer owned 73,485 shares in the company, valued at approximately $313,046.10. This represents a 16.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price target on shares of Precision BioSciences in a research report on Wednesday, May 21st.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.